Overview

Nepafenac 0.3% Two Study

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.

Phase:

Phase 2

Details

Lead Sponsor:

Alcon Research

Treatments:

Nepafenac